Analyst Ratings For Aridis Pharmaceuticals Inc (NASDAQ:ARDS)

Today, Laidlaw initiated coverage on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) with a Buy with a price target of $23.00.

There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) is Buy with a consensus target price of $24.00 per share, a potential 98.02% upside.

Some recent analyst ratings include

• 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Buy rating and $23.00 price target
• 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Overweight rating

Recent Trading Activity for Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
Shares of Aridis Pharmaceuticals Inc closed the previous trading session at 12.12 −1.18 8.87% with 13.46 shares trading hands.